Voltage-gated Na(+) Channel Blockers Reduce Functional Bladder Capacity in the Conscious Spontaneously Hypertensive Rat.

Autor: Clouse AK (AUTHOR), Jugus MJ (AUTHOR), Eisennagel SH (AUTHOR), Laping NJ (AUTHOR), Westfall TD (AUTHOR), Thorneloe KS (AUTHOR)

Publikováno v: Urology. Jun2012, Vol. 79 Issue 6, p1410.e1-6. 1p.

The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs.

Autor: Virtue AT; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., McCright SJ; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Wright JM; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Jimenez MT; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Mowel WK; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Kotzin JJ; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Joannas L; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Basavappa MG; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA., Spencer SP; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Clark ML; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Eisennagel SH; Core DMPK, GlaxoSmithKline, Collegeville, PA 19426, USA., Williams A; Jackson Laboratory for Genomic Medicine, Department of Genetics and Genome Sciences, University of Connecticut Health Center, Farmington, CT 06032, USA., Levy M; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel., Manne S; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, Philadelphia, PA 19104, USA., Henrickson SE; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Division of Allergy Immunology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., Wherry EJ; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, Philadelphia, PA 19104, USA.; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Thaiss CA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel., Elinav E; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel., Henao-Mejia J; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. jhena@pennmedicine.upenn.edu.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Division of Protective Immunity, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2019 Jun 12; Vol. 11 (496).

Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.

Autor: Qin P; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA pu.2.qin@gsk.com., Arabacilar P; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Bernard RE; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Bao W; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Olzinski AR; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Guo Y; Basic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN., Lal H; Basic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN., Eisennagel SH; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Platchek MC; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Xie W; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Del Rosario J; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Nayal M; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Lu Q; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Roethke T; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Schnackenberg CG; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Wright F; Preclinical and Translational Imaging, Platform Technology and Science, GlaxoSmithKline, King of Prussia, PA., Quaile MP; Preclinical and Translational Imaging, Platform Technology and Science, GlaxoSmithKline, King of Prussia, PA., Halsey WS; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Hughes AM; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Sathe GM; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Livi GP; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Kirkpatrick RB; Pipeline Future's Group, GlaxoSmithKline, King of Prussia, PA., Qu XA; Computational Biology, Projects Clinical Platforms and Sciences, GlaxoSmithKline, King of Prussia, PA., Rajpal DK; Computational Biology, Projects Clinical Platforms and Sciences, GlaxoSmithKline, King of Prussia, PA., Faelth Savitski M; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA., Bantscheff M; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA., Joberty G; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA., Bergamini G; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA., Force TL; Basic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN., Gatto GJ Jr; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Hu E; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Willette RN; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.

Publikováno v: Journal of the American Heart Association [J Am Heart Assoc] 2017 May 09; Vol. 6 (5). Date of Electronic Publication: 2017 May 09.

Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice.

Autor: Morgan LA; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area Unit, GlaxoSmithKline, King of Prussia, PA 19406-0939, USA., Olzinski AR, Upson JJ, Zhao S, Wang T, Eisennagel SH, Hoang B, Tunstead JR, Marino JP Jr, Willette RN, Jucker BM, Behm DJ

Publikováno v: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2013 Apr; Vol. 61 (4), pp. 291-301.